ALPN | tickerfilter.com

Fundamental analysis

23%

Profitability 25%

Dept financing 10%

Liquidity 48%

Performance 18%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

226.15%

2 Year

947.90%

Key data

Stock price

$64.98

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$18.33 - $65.00

52 WEEK CHANGE

$240.87

MARKET CAP

650.896 M

YIELD

N/A

SHARES OUTSTANDING

47.966 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.90

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Mitchell H. Gold
Region: US
Website: alpineimmunesciences.com
Employees: 80
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the. treatment of autoimmune and inflammatory diseases.

ALPN - ALPINE IMMUNE SCIENCES, INC.